Asserta applications allow you to analyze vast amounts of data from treatments, diagnoses, analytical results, as well as other systems and devices that contain health data. In this way, they help healthcare organizations obtain very valuable information to identify the most effective treatment procedures while minimizing healthcare costs.
They were just at MWC and the biggest star at their booth was the multi-platform Fleming app.
Our service portfolio includes other solutions such as OncoAnalytics or Pharmacy Analytics Manager (PAM). However, when we were offered the opportunity to attend MWC24, it was clear to us that it was the perfect place to showcase our cross-platform and multi-language application Fleming – Antimicrobial Stewardship (Fleming-PROA for Spain and Latin America).
The Fleming-PROA application structures and integrates all data related to antibiotic use, diagnoses, microbiological laboratory analysis results and other relevant clinical data. From this data, the application automatically calculates and generates all indicators related to resistance and susceptibility of the local microbial ecosystem, population exposure to antibiotics and health outcomes.
This allows healthcare professionals to have real-time information that enables early detection of problems and early intervention to solve them, facilitating clinical decision-making and effective use of antimicrobials based on constantly updated and available data.
Josep Monterde is the founder and CEO of Asserta
Why is this important?
There are studies that indicate that a total of 4.95 million deaths related to microbial resistance occurred worldwide in 2019, of which more than 1.2 million were a direct result of multidrug-resistant microorganisms. What are popularly called supermicrobes or superbacteria.
WHO and the United Nations, among others, issue global warnings and publish recommendations to address the problem.
Projections suggest that if nothing new is done to prevent this, by 2050 this number could reach 10 million deaths per year caused by multidrug-resistant microorganisms.
This situation may even threaten our ability to treat common infections or perform life-saving procedures such as chemotherapy, caesarean sections, hip replacements, organ transplants and other operations where the availability of effective antibiotics is essential.
“Fleming-PROA structures and integrates all data related to the use of antibiotics,
diagnoses, analytical results
microbiological laboratory and other relevant clinical data’
How can Fleming contribute to reducing the spread of these resistances?
Bacterial resistance patterns may vary by geographic area or even within the same health area, and may also change over time. For this reason, it is very important that health professionals, doctors, pharmacists and nurses in hospitals and ambulatory care centers have constantly updated information about the resistance and susceptibility of microorganisms in their environment to the various therapeutic options available. In this way, they can adapt their infectious disease treatment protocols to the reality of the microbial ecosystem in their environment.
Unfortunately, in many cases pharmacists, microbiologists and infectious disease specialists are forced to prepare this information manually.
The large presence of health professionals in their team is striking.
It was our previous health experiences that made it clear to us that this should be the case. Thanks to the deep knowledge of the area in which the technology needs to be applied, the solutions are more adapted to the real needs of the professionals who have to use them, in an easy and intuitive way. We didn’t want to be a technology company, but rather a healthcare services company that designs and implements health analytics solutions, specializes in the pharmacotherapy process, and has an experienced and immensely talented human team.
About Josep Monterde, Founder and CEO
He is a doctor of pharmacy and specialist in hospital pharmacy and has extensive medical, research and academic experience at an international level. With an innovative profile, his professional career is characterized by his strategic vision, the design and implementation of breakthrough solutions and his commitment to the effective and safe use of medicines.
He is recognized with various awards and honors at the international level, has organized more than 300 conferences and round tables in different countries and has around 100 publications including articles, books and book chapters. He was vice-president of the Academy of Medical Sciences of Catalonia and the Balearic Islands and a member of various national and international scientific societies; In addition, he has advised and advises various health authorities, universities, technology schools, and public and private health centers in several countries.
